HORSHAM, Pa., Nov. 01, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:SSKN) STRATA Skin Sciences, Inc. ("STRATA") a medical technology company dedicated to developing and commercializing innovative products for the treatment and diagnosis of serious dermatological disorders, today announced that its Board of Directors has named Mr. McCaney, 61, as the company's next President and Chief Executive Officer, effective November 1, 2016. Mr. McCaney replaces Michael Stewart, who has resigned as President and CEO and member of the Board of Directors, effective immediately. Mr. Stewart has agreed to remain with STRATA as an independent consultant to assist in both commercial and clinical aspects of the company's continued growth. Jeffrey O'Donnell Sr., Chairman of the Board of STRATA Skin Sciences, stated, "The Board thanks Mike Stewart for his tireless efforts and dedication to Strata Skin Sciences. We are confident that Frank McCaney has the skill sets to build the company into a major innovator and partner to dermatologists and their clinical teams. We look forward to building the value in this changing environment." In expressing his views on his reasons for joining STRATA and his visions for the company's growth, Mr. McCaney stated, "The core business of Strata is healthy and I believe that there is significant potential for growth both in the core business and in expanding the company's business model to better serve both dermatologists and patients." Mr. McCaney was most recently CEO of Corpak MedSystems, a private equity-backed medical device company in the field of enteral feeding. Corpak was sold to Halyard Health (NYSE:HYH) for $174 million in May 2016. Prior to Corpak, he was the founder and CEO of Nitric BioTherapeutics, a venture backed-medical technology company from 2006 until 2012. Prior to Nitric Bio, he was a senior executive at Viasys Healthcare, Inc., a medical technology company focusing on respiratory, neurology, medical disposable and orthopedic products and had a lead role in spinning Viasys out of Thermo Electron Corporation. While at Viasys, Mr. McCaney had several responsibilities including strategy, business development and investor relations. He currently serves as a director of Diasome Pharmaceuticals, a privately-held company.